Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 123

1.

Increasing vaccine potency through exosome antigen targeting.

Hartman ZC, Wei J, Glass OK, Guo H, Lei G, Yang XY, Osada T, Hobeika A, Delcayre A, Le Pecq JB, Morse MA, Clay TM, Lyerly HK.

Vaccine. 2011 Nov 21;29(50):9361-7. doi: 10.1016/j.vaccine.2011.09.133. Epub 2011 Oct 12.

2.

Targeting tumor antigens to secreted membrane vesicles in vivo induces efficient antitumor immune responses.

Zeelenberg IS, Ostrowski M, Krumeich S, Bobrie A, Jancic C, Boissonnas A, Delcayre A, Le Pecq JB, Combadière B, Amigorena S, Théry C.

Cancer Res. 2008 Feb 15;68(4):1228-35. doi: 10.1158/0008-5472.CAN-07-3163.

3.

Exosomes as novel therapeutic nanodevices.

Delcayre A, Le Pecq JB.

Curr Opin Mol Ther. 2006 Feb;8(1):31-8. Review.

PMID:
16506523
4.

[Round table chaired by Laurent Broomhead].

Ménard J, Le Fur G, Le Pecq JB, Saliou P, Weissenbach J, Potier P.

Ann Pharm Fr. 2005 Sep;63(5):312-28. French. No abstract available.

PMID:
16385780
5.

Exosome Display technology: applications to the development of new diagnostics and therapeutics.

Delcayre A, Estelles A, Sperinde J, Roulon T, Paz P, Aguilar B, Villanueva J, Khine S, Le Pecq JB.

Blood Cells Mol Dis. 2005 Sep-Oct;35(2):158-68.

PMID:
16087368
6.

An analysis of variability in the manufacturing of dexosomes: implications for development of an autologous therapy.

Patel S, Mehta-Damani A, Shu H, Le Pecq JB.

Biotechnol Bioeng. 2005 Oct 20;92(2):238-49.

PMID:
16037986
7.

Dexosomes as a therapeutic cancer vaccine: from bench to bedside.

Le Pecq JB.

Blood Cells Mol Dis. 2005 Sep-Oct;35(2):129-35. Review.

PMID:
16024263
8.

Dendritic cell-derived exosomes in cancer immunotherapy: exploiting nature's antigen delivery pathway.

Delcayre A, Shu H, Le Pecq JB.

Expert Rev Anticancer Ther. 2005 Jun;5(3):537-47. Review.

PMID:
16001959
9.

Vaccination of metastatic melanoma patients with autologous dendritic cell (DC) derived-exosomes: results of thefirst phase I clinical trial.

Escudier B, Dorval T, Chaput N, André F, Caby MP, Novault S, Flament C, Leboulaire C, Borg C, Amigorena S, Boccaccio C, Bonnerot C, Dhellin O, Movassagh M, Piperno S, Robert C, Serra V, Valente N, Le Pecq JB, Spatz A, Lantz O, Tursz T, Angevin E, Zitvogel L.

J Transl Med. 2005 Mar 2;3(1):10.

10.

A phase I study of dexosome immunotherapy in patients with advanced non-small cell lung cancer.

Morse MA, Garst J, Osada T, Khan S, Hobeika A, Clay TM, Valente N, Shreeniwas R, Sutton MA, Delcayre A, Hsu DH, Le Pecq JB, Lyerly HK.

J Transl Med. 2005 Feb 21;3(1):9.

11.

Exosomes as a tumor vaccine: enhancing potency through direct loading of antigenic peptides.

Hsu DH, Paz P, Villaflor G, Rivas A, Mehta-Damani A, Angevin E, Zitvogel L, Le Pecq JB.

J Immunother. 2003 Sep-Oct;26(5):440-50.

PMID:
12973033
12.

Production and characterization of clinical grade exosomes derived from dendritic cells.

Lamparski HG, Metha-Damani A, Yao JY, Patel S, Hsu DH, Ruegg C, Le Pecq JB.

J Immunol Methods. 2002 Dec 15;270(2):211-26.

PMID:
12379326
13.

Another link between phospholipid transmembrane migration and ABC transporter gene family, inferred from a rare inherited disorder of phosphatidylserine externalization.

Toti F, Schindler V, Riou JF, Lombard-Platet G, Fressinaud E, Meyer D, Uzan A, Le Pecq JB, Mandel JL, Freyssinet JM.

Biochem Biophys Res Commun. 1997 Dec 18;241(2):548-52.

PMID:
9425308
14.

Betulinic acid derivatives: a new class of specific inhibitors of human immunodeficiency virus type 1 entry.

Soler F, Poujade C, Evers M, Carry JC, Hénin Y, Bousseau A, Huet T, Pauwels R, De Clercq E, Mayaux JF, Le Pecq JB, Dereu N.

J Med Chem. 1996 Mar 1;39(5):1069-83.

PMID:
8676342
15.

Betulinic acid derivatives: a new class of human immunodeficiency virus type 1 specific inhibitors with a new mode of action.

Evers M, Poujade C, Soler F, Ribeill Y, James C, Lelièvre Y, Gueguen JC, Reisdorf D, Morize I, Pauwels R, De Clercq E, Hénin Y, Bousseau A, Mayaux JF, Le Pecq JB, Dereu N.

J Med Chem. 1996 Mar 1;39(5):1056-68.

PMID:
8676341
17.

Asymmetrically substituted ethylenediamine platinum(II) complexes as antitumor agents: synthesis and structure-activity relationships.

Mailliet P, Segal-Bendirdjian E, Kozelka J, Barreau M, Baudoin B, Bissery MC, Gontier S, Laoui A, Lavelle F, Le Pecq JB, et al.

Anticancer Drug Des. 1995 Jan;10(1):51-73.

PMID:
7695813
18.

Structure-activity relationships in a series of 5-[(2,5-dihydroxybenzyl)amino]salicylate inhibitors of EGF-receptor-associated tyrosine kinase: importance of additional hydrophobic aromatic interactions.

Chen H, Boiziau J, Parker F, Mailliet P, Commerçon A, Tocque B, Le Pecq JB, Roques BP, Garbay C.

J Med Chem. 1994 Mar 18;37(6):845-59.

PMID:
8145236
19.

Synthesis and biological activity of new dimers in the 7H-pyrido[4,3-c] carbazole antitumor series.

Garbay-Jaureguiberry C, Barsi MC, Jacquemin-Sablon A, Le Pecq JB, Roques BP.

J Med Chem. 1992 Jan;35(1):72-81.

PMID:
1732535
20.

Removal of DNA curving by DNA ligands: gel electrophoresis study.

Barcelo F, Muzard G, Mendoza R, Révet B, Roques BP, Le Pecq JB.

Biochemistry. 1991 May 21;30(20):4863-73.

PMID:
1645181
21.

[Genomic pharmacology].

Bracco L, Le Pecq JB.

Arch Mal Coeur Vaiss. 1991 Feb;84(2):219-25. French.

PMID:
2021283
22.

Comparative cytotoxicities of a series of ellipticine and olivacine derivatives on multidrug resistant cells of human and murine origins.

Chevallier-Multon MC, Jacquemin-Sablon A, Besselièvre R, Husson HP, Le Pecq JB.

Anticancer Drug Des. 1990 Nov;5(4):319-35.

PMID:
1981310
23.

DNase I susceptibility of bent DNA and its alteration by ditercalinium and distamycin.

Mendoza R, Markovits J, Jaffrezou JP, Muzard G, Le Pecq JB.

Biochemistry. 1990 May 29;29(21):5035-43.

PMID:
2198937
24.
25.
26.

Recognition by the DNA repair system of DNA structural alterations induced by reversible drug-DNA interactions.

Lambert B, Segal-Bendirdjian E, Esnault C, Le Pecq JB, Roques BP, Jones B, Yeung AT.

Anticancer Drug Des. 1990 Feb;5(1):43-53.

PMID:
2180423
27.

Selective alteration of mitochondrial function by Ditercalinium (NSC 335153), a DNA bisintercalating agent.

Esnault C, Brown SC, Segal-Bendirdjian E, Coulaud D, Mishal Z, Roques BP, Le Pecq JB.

Biochem Pharmacol. 1990 Jan 1;39(1):109-22.

PMID:
2297352
28.

Mechanisms of action in NIH-3T3 cells of genistein, an inhibitor of EGF receptor tyrosine kinase activity.

Linassier C, Pierre M, Le Pecq JB, Pierre J.

Biochem Pharmacol. 1990 Jan 1;39(1):187-93.

PMID:
2153378
29.
30.

Inhibitory effects of the tyrosine kinase inhibitor genistein on mammalian DNA topoisomerase II.

Markovits J, Linassier C, Fossé P, Couprie J, Pierre J, Jacquemin-Sablon A, Saucier JM, Le Pecq JB, Larsen AK.

Cancer Res. 1989 Sep 15;49(18):5111-7.

31.
32.

Acridine dimers: influence of the intercalating ring and of the linking-chain nature on the equilibrium and kinetic DNA-binding parameters.

Markovits J, Garbay-Jaureguiberry C, Roques BP, Le Pecq JB.

Eur J Biochem. 1989 Mar 15;180(2):359-66.

33.

Cytoplasmic accumulation of ditercalinium in rat hepatocytes and induction of mitochondrial damage.

Fellous R, Coulaud D, el Abed I, Roques BP, Le Pecq JB, Delain E, Gouyette A.

Cancer Res. 1988 Nov 15;48(22):6542-9.

34.

Selective loss of mitochondrial DNA after treatment of cells with ditercalinium (NSC 335153), an antitumor bis-intercalating agent.

Segal-Bendirdjian E, Coulaud D, Roques BP, Le Pecq JB.

Cancer Res. 1988 Sep 1;48(17):4982-92.

35.
36.

Cationic porphyrin-DNA interactions: importance of the number and position of the charges.

Sari MA, Battioni JP, Dupre D, Mansuy D, Le Pecq JB.

Biochem Pharmacol. 1988 May 1;37(9):1861-2. No abstract available.

PMID:
3377854
37.

Asymmetrical bisintercalators as potential antitumor agents.

Léon P, Garbay-Jaureguiberry C, Lambert B, Le Pecq JB, Roques BP.

J Med Chem. 1988 May;31(5):1021-6.

PMID:
3283364
38.

Kinetic analysis of choriocarcinoma cell intoxication induced by ricin and ricin A chain immunotoxin.

Braham K, Junqua S, Tursz T, Le Pecq JB, Lipinski M.

Cancer Res. 1988 Feb 15;48(4):806-11.

40.

Modulation of the antitumor activity by methyl substitutions in the series of 7H-pyridocarbazole monomers and dimers.

Léon P, Garbay-Jaureguiberry C, Barsi MC, Le Pecq JB, Roques BP.

J Med Chem. 1987 Nov;30(11):2074-80.

PMID:
3669015
41.

Synthesis and binding properties to DNA and to opioid receptors of enkephalin-ellipticinium conjugates.

Rigaudy P, Garbay-Jaureguiberry C, Jacquemin-Sablon A, Le Pecq JB, Roques BP.

Int J Pept Protein Res. 1987 Sep;30(3):347-55.

PMID:
2826357
42.

Geometry of the antitumor drug ditercalinium bisintercalated into d(CpGpCpG)2 by 1H NMR.

Delbarre A, Delepierre M, Garbay C, Igolen J, Le Pecq JB, Roques BP.

Proc Natl Acad Sci U S A. 1987 Apr;84(8):2155-9.

43.

DNA bis-intercalators as new anti-tumour agents: modulation of the anti-tumour activity by the linking chain rigidity in the ditercalinium series.

Garbay-Jaureguiberry C, Laugâa P, Delepierre M, Laalami S, Muzard G, Le Pecq JB, Roques BP.

Anticancer Drug Des. 1987 Apr;1(4):323-35.

PMID:
3450302
45.

Rational design of bis-intercalating drugs as antitumour agents: importance of rigidity in the linking chain.

Garbay-Jaureguiberry C, Esnault C, Delepierre M, Laugaa P, Laalami S, Le Pecq JB, Roques BP.

Drugs Exp Clin Res. 1987;13(6):353-7.

PMID:
3652924
46.
47.

Mode of interaction and apparent binding constants of meso-tetraaryl porphyrins bearing between one and four positive charges with DNA.

Sari MA, Battioni JP, Mansuy D, Le Pecq JB.

Biochem Biophys Res Commun. 1986 Dec 15;141(2):643-9.

PMID:
3801018
49.

Effects of the bifunctional antitumor intercalator ditercalinium on DNA in mouse leukemia L1210 cells and DNA topoisomerase II.

Markovits J, Pommier Y, Mattern MR, Esnault C, Roques BP, Le Pecq JB, Kohn KW.

Cancer Res. 1986 Nov;46(11):5821-6.

50.

Supplemental Content

Loading ...
Support Center